Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...
The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...
A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback